Schizophrenia: Recent advances in psychopharmacology

British Journal of Hospital Medicine

Volumn 55, Issue 4, 1996, Pages 194-198

  Sharma, Tonmoy ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; PSYCHOLOGY; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0030596258     PISSN: 00071064     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Borison RL, Pathiraja AP, Diamond BI, Meibach RC (1992) Rispendone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28(2): 213-18
2. Dittmann RW (1993) Olanzapine: pharmacological characteristics and first clinical experiences. Pharmacopsychiatry 26: 147
3. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psych 45(9): 789-96
4. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA (1993) Does clozapine cause tardive dyskinesia? J Clin Psychiatr 54(9): 327-30
5. Lee MA, Thompson PA, Meltzer HY (1994) Effects of clozapine on cognitive function in schizophrenia. J Chn Psychiatr 55(suppl B): 82-7
6. Lieberman JA, Kane JM, Johns CA (1989) Clozapine: guidelines for clinical management./ Clin Psychiatr 50(9): 329-38
7. Lieberman JA, Yums J, Egea E, Canoso RT, Kane JM, Yunis EJ (1990) HLA-B38, DR4, DCjw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatr 47(10j): 945-8
8. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstem M, Kane J (1991) The effects of clozapine on tardive dyskinesia. Br J Psychiatr 158: 503-10
9. Lieberman JA, Kane JM, Safferman AZ et al (1994) Predictors of response to clozapine./ Clin Psychiatr 55(suppl IB): 126-8
10. Livingston MG (1994) Risperidone. Lancet 343(8895): 457-60
11. LMS R&D Profiles (1995) Psychotic Disorders. Adis International, New Zealand
12. Mallya AR, Roos PD, Roebuck Colgan K (1992) Restraint, seclusion, and clozapine./ Clin Psychiatr 53(11): 395-7
13. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am ] Psychiatr 151(6): 825-35
14. Meltzer HY (1992) The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY, ed. Novel Antipsychotic Drugs. Raven Press, New York: 1-13
15. Meltzer HY, Cola PA (1994) The pharmacoeconomics of clozapine: a review. J Clin Psychiatr 55(Suppl B): 161-5
16. Meltzer HY, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatr 152(2): 183-90
17. Meltzer HY, Lee MA, Ranjan R (1994) Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl 384: 95-101
18. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Citrr Opin Invest Drugs 2(4): 2281-93
19. Schooler NR (1994) Negative symptoms in schizophrenia: assessment of the effect of rispendone. J Clin Psychiatr 55(suppl): 22-8
20. Seeger TF, Seymour PA, Schmidt AW et al. (19,95) Ziprasidone (CP-88,059) a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275(1): 101-13
21. Wetzel H, Szgedi A, Hain C, Wiesner J, Schlegel S, Benkert O (1995) Serpquel (ICI 204 636), a putative 'atypical' antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG Çarameters. Gen Psychopharmacol Berlin 19:231-8